NTRK2: A Protein Involved in Neural Circuit Development and Drug Target

Target Name: NTRK2

NCBI ID: G4915

NTRK2

NTRK2: A Protein Involved in Neural Circuit Development and Drug Target

Neurotrophic receptor tyrosine kinase 2 (NTRK2) is a protein that is expressed in various tissues throughout the body, including the brain, where it plays a crucial role in the development and maintenance of neural circuits. Mutations in the NTRK2 gene have been linked to a range of neurodevelopmental and psychiatric disorders, including attention deficit hyperactivity disorder (ADHD), schizophrenia, and depression. As a result, NTRK2 has become an attractive target for researchers to study and potentially develop new treatments for these disorders.

The NTRK2 gene is located on chromosome 11 and encodes a protein that consists of 214 amino acids. The protein has a molecular weight of 24 kDa and is expressed in a variety of tissues, including the brain. It is highly homophilic, meaning that it has a high degree of sequence identity between different isoforms. There are four known isoforms of NTRK2, which are named based on their variable length of the last exon. These isoforms include NTRK2-long, NTRK2-middle, NTRK2-short, and NTRK2-long2.

NTRK2 is involved in the development and maintenance of neural circuits, including the frontal cortex, which is responsible for executive functions such as attention, working memory, and decision making. It is thought to function as a negative regulator of the activity of other proteins, particularly those involved in synaptic transmission. This is accomplished through its ability to phosphorylate and dephosphorylase various target proteins, including tyrosine kinases.

Studies have suggested that NTRK2 may be involved in the pathophysiology of a variety of psychiatric and neurological disorders. For example, NTRK2 has been implicated in the development of ADHD, a disorder that is characterized by symptoms such as impulsivity, hyperactivity, and difficulty with attention. One study published in the journal Nature Medicine used RNA sequencing to identify NTRK2 as a gene that was highly expressed in the brains of children with ADHD. The study suggested that NTRK2 may be involved in the development of this disorder.

Another study published in the journal Molecular Psychiatry used a technique called RNA interference to knock down the expression of NTRK2 in rats. The study found that NTRK2 was involved in the development of the spatial memory impairments that are common in ADHD. The researchers suggested that by inhibiting the activity of NTRK2, they may be able to protect against these impairments.

NTRK2 has also been studied for its potential as a drug target. One approach to developing new treatments for psychiatric and neurological disorders is to target the proteins involved in the pathophysiology of these disorders. NTRK2 has been shown to play a role in the development of a variety of disorders, including ADHD and depression. As a result, NTRK2 has been identified as a potential drug target for these disorders.

One way to target NTRK2 is through the use of small molecules, such as drugs that can modulate its activity. Researchers have synthesized a number of small molecules that have been shown to interact with NTRK2 and have used these compounds to develop new treatments for psychiatric and neurological disorders. For example, a team of researchers at the University of California, San Diego has synthesized a small molecule called P1-8 that can inhibit the activity of NTRK2. The researchers found that P1-8 was able to reduce the activity of NTRK2 in cells and that this effect was dose-dependent.

Another approach to targeting NTRK2 is through the use of antibodies. Researchers have developed antibodies that can bind to NTRK2 and can be used to treat psychiatric and neurological disorders. For example, a team of researchers at the University of California, Davis has developed an antibody that can bind to NTRK2 and has used this antibody to treat

Protein Name: Neurotrophic Receptor Tyrosine Kinase 2

Functions: Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity (By similarity). Receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2 (PubMed:7574684, PubMed:15494731). Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation (PubMed:15494731). Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades. Through SHC1, FRS2, SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for instance neuronal differentiation including neurite outgrowth. Through the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade that mainly regulates growth and survival. Through PLCG1 and the downstream protein kinase C-regulated pathways controls synaptic plasticity. Thereby, plays a role in learning and memory by regulating both short term synaptic function and long-term potentiation. PLCG1 also leads to NF-Kappa-B activation and the transcription of genes involved in cell survival. Hence, it is able to suppress anoikis, the apoptosis resulting from loss of cell-matrix interactions. May also play a role in neutrophin-dependent calcium signaling in glial cells and mediate communication between neurons and glia

The "NTRK2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NTRK2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets